Having established clear evidence of tau pathology in the brains of patients with Huntington’s disease, and a possible interaction with mutant HTT aggregates, we then investigated whether MAPT haplotypes—known to alter the expression of tau isoforms—had any impact on the development and clinical expression of Huntington’s disease using genotype-phenotype analysis. The gene discussed is MAPT; the disease is juvenile Huntington disease.